Decoy exosomes as a novel biologic reagent to antagonize inflammation

References

• Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12(Suppl 1):S3–S9.16378007
   PubMed Web of Science ®Google Scholar
• Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1316–1322. doi:10.1136/annrheumdis-2013-20462724550173
   PubMed Web of Science ®Google Scholar
• Schon MP. Advances in psoriasis treatment. Lancet. 2005;366:1333–1335. doi:10.1016/S0140-6736(05)67542-316226595
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340:115–126. doi:10.1056/NEJM1999011434002079887164
   PubMed Web of Science ®Google Scholar
• Rhee C, Gohil S, Klompas M. Regulatory mandates for sepsis care – reasons for caution. N Engl J Med. 2014;370:1673–1676. doi:10.1056/NEJMp140027624738642
   PubMed Web of Science ®Google Scholar
• Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord. 2000;14(Suppl 1):S47–S53.10850730
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008;267:204–215. doi:10.1016/j.canlet.2008.03.02818448242
   PubMed Web of Science ®Google Scholar
• Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992;14:309–317.1607607
   PubMed Web of Science ®Google Scholar
• Wimo, A., Guerchet, M, Ali, GC, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2016;13:1–7. doi:10.1016/j.jalz.2016.07.15027583652
   PubMed Web of Science ®Google Scholar
• Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2000;39:28–33.10662870
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369:754–762. doi:10.1056/NEJMct120961423964937
   PubMed Web of Science ®Google Scholar
• Straub RH, Schradin C. Chronic inflammatory systemic diseases: an evolutionary trade-off between acutely beneficial but chronically harmful programs. Evol Med Public Health. 2016;2016:37–51. doi:10.1093/emph/eow00126817483
   PubMedGoogle Scholar
• Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002;2:725–734. doi:10.1038/nri91012360211
   PubMed Web of Science ®Google Scholar
• Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2:244–247.2569055
   PubMed Web of Science ®Google Scholar
• Coskun M, Nielsen OH. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369:2561–2562. doi:10.1056/NEJMc1312800
   PubMedGoogle Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022. doi:10.1056/NEJMoa03040914627786
   PubMed Web of Science ®Google Scholar
• Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence. 2009;3:335–344.20016797
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–608. doi:10.1056/NEJMoa02088812584368
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806. doi:10.1002/art.2202516947627
   PubMed Web of Science ®Google Scholar
• de Vries MK, Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis. 2007;66:1252–1254. doi:10.1136/ard.2007.07239717472991
   PubMed Web of Science ®Google Scholar
• De Benedetti, F., Brunner, HI, Ruperto, N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395. doi:10.1056/NEJMoa111280223252525
   PubMed Web of Science ®Google Scholar
• Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn’s disease. Drug Discov Today. 2007;12:125–131. doi:10.1016/j.drudis.2006.11.01317275732
   PubMed Web of Science ®Google Scholar
• Kowal J, Tkach M, Thery C. Biogenesis and secretion of exosomes. Curr Opin Cell Biol. 2014;29:116–125. doi:10.1016/j.ceb.2014.05.00424959705
   PubMed Web of Science ®Google Scholar
• Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–289. doi:10.1146/annurev-cellbio-101512-12232625288114
   PubMed Web of Science ®Google Scholar
• Mittelbrunn M, Sanchez-Madrid F. Intercellular communication: diverse structures for exchange of genetic information. Nat Rev Mol Cell Biol. 2012;13:328–335. doi:10.1038/nrm333522510790
   PubMed Web of Science ®Google Scholar
• Yim, N., Ryu, SW, Choi, K, et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein–protein interaction module. Nat Commun. 2016;7:12277. doi:10.1038/ncomms1227727447450
   PubMed Web of Science ®Google Scholar
• Alvarez-Erviti, L., Seow, Y, Yin, H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341–345. doi:10.1038/nbt.180721423189
   PubMed Web of Science ®Google Scholar
• Kamerkar, S., LeBleu, VS, Sugimoto, H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546:498–503. doi:10.1038/nature2234128607485
   PubMed Web of Science ®Google Scholar
• Stickney Z, Losacco J, McDevitt S, Zhang Z, Lu B. Development of exosome surface display technology in living human cells. Biochem Biophys Res Commun. 2016;472:53–59. doi:10.1016/j.bbrc.2016.02.05826902116
   PubMed Web of Science ®Google Scholar
• Marcus ME, Leonard JN. FedExosomes: engineering therapeutic biological nanoparticles that truly deliver. Pharmaceuticals (Basel). 2013;6:659–680. doi:10.3390/ph605065923894228
   PubMedGoogle Scholar
• Kowal, J., Arras, G, Colombo, M, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A. 2016;113:E968–E977. doi:10.1073/pnas.152123011326858453
   PubMed Web of Science ®Google Scholar
• Afshari A, Uhde-Stone C, Lu B. Live visualization and quantification of pathway signaling with dual fluorescent and bioluminescent reporters. Biochem Biophys Res Commun. 2014;448:281–286. doi:10.1016/j.bbrc.2014.04.10824792187
   PubMedGoogle Scholar
• Meyer, C., Losacco, J, Stickney, Z, et al. Pseudotyping exosomes for enhanced protein delivery in mammalian cells. Int J Nanomedicine. 2017;12:3153–3170. doi:10.2147/IJN.S13343028458537
   PubMed Web of Science ®Google Scholar
• Van Deun, J., Mestdagh, P, Agostinis, P, et al. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Methods. 2017;14:228–232. doi:10.1038/nmeth.418528245209
   PubMed Web of Science ®Google Scholar
• Afshari A, Uhde-Stone C, Lu B. A cooled CCD camera-based protocol provides an effective solution for in vitro monitoring of luciferase. Biochem Biophys Res Commun. 2015;458:543–548. doi:10.1016/j.bbrc.2015.01.15025677617
   PubMedGoogle Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75:1–18. doi:10.1016/j.colsurfb.2009.09.00119782542
   PubMed Web of Science ®Google Scholar
• Sahay, G., Querbes, W, Alabi, C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 2013;31:653–658. doi:10.1038/nbt.261423792629
   PubMed Web of Science ®Google Scholar
• Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J. 1997;11:428–442.9194523
   PubMed Web of Science ®Google Scholar
• Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. Exp Cell Res. 2009;315:1584–1592. doi:10.1016/j.yexcr.2008.09.02018930046
   PubMed Web of Science ®Google Scholar
• Lu B, Moser A, Shigenaga JK, Grunfeld C, Feingold KR. The acute phase response stimulates the expression of angiopoietin like protein 4. Biochem Biophys Res Commun. 2010;391:1737–1741. doi:10.1016/j.bbrc.2009.12.14520043872
   PubMed Web of Science ®Google Scholar
• Lu B, Lu Y, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. LPS and proinflammatory cytokines decrease lipin-1 in mouse adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2008;295:E1502–E1509. doi:10.1152/ajpendo.90323.200818940942
   PubMedGoogle Scholar
• Wang Y, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Downregulation of liver X receptor-alpha in mouse kidney and HK-2 proximal tubular cells by LPS and cytokines. J Lipid Res. 2005;46:2377–2387. doi:10.1194/jlr.M500134-JLR20016106051
   PubMedGoogle Scholar
• Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med. 1991;174:1483–1489.1660525
   PubMed Web of Science ®Google Scholar
• Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989;264:11974–11980.2545693
   PubMed Web of Science ®Google Scholar
• Moreland LW, Heck LW Jr., Koopman WJ. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum. 1997;40:397–409.9082924
   PubMed Web of Science ®Google Scholar
• Griffiths, CE, Strober, BE, van de Kerkhof, P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–128. doi:10.1056/NEJMoa081065220071701
   PubMed Web of Science ®Google Scholar
• Tvete IF, Natvig B, Gåsemyr J, et al. Comparing effects of biologic agents in treating patients with rheumatoid arthritis: a multiple treatment comparison regression analysis. PLoS One. 2015;10:e0137258. doi:10.1371/journal.pone.013725826356639
   PubMedGoogle Scholar
• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328–335. doi:10.1016/j.bbrc.2005.05.13215961063
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400. doi:10.1038/nrd138115136787
   PubMed Web of Science ®Google Scholar